Complementing pathological analyses, these intriguing results are expected to demonstrate that radiolabeled HZ20 analogs have substantial value in quantifying the ACE2 distribution in the entire body, and monitoring the transient upregulation of ACE2 expression to guide patient management and evaluate therapeutic intervention of COVID‐19 patients. The gene discussed is ACE2; the disease is COVID-19.